Fenquizone is a diuretic drug that is classified as a quinazolinone and a sulphonamide drug. It has similar activities to thiazide diuretics. This drug is utilized in the treatment of edema and high blood pressure.
It is slightly related to the drug metolazone and has a thiazide-like function. As a thiazide-like diuretic, fenquizone can block the reabsorption of sodium in the proximal tubule and the ascending loop of Henle. This causes an increase in diuresis by eliminating chloride and sodium. Some of the pharmacological actions of this diuretic drug have been studied in mice, rats, and rabbits. Some changes in sodium and potassium excretion and changes in urine volume were greater in magnitude and duration when compared to other thiazide diuretics at a dose range of 0.05 to 100 mg. In rabbits, free water clearance was decreased due to its actions on the cortical diluting site of the nephron and, since free water that was absorbed was relatively unaffected, it appears unlikely that it has other actions in other sites. Some studies claim that the predominant effects of this drug are those occurring at the cortical diluting segment of the nephron relating to calcium and phosphate. Blood flow to the cortex and the medulla of the kidney (and other major organs), plasma glucose concentration and plasma urate concentration are additional parameters that are not affected by the drug.
